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EDITORIAL REVIEW
A molecular approach to inherited kidney disorders
In recent years there has been an explosive growth in our
knowledge of the molecular genetics in many inherited disor-
ders. This breakthrough has been made possible by dramatic
advances in DNA technology. Two main approaches have been
used in monogenic hereditary diseases. In classical genetics,
specific proteins whose defects are characteristic of the dis-
eases were first identified, leading to further identification of the
corresponding genes and of their molecular defect(s). This
approach is exemplified in hemoglobinopathies, in hemophilias
and in various inherited metabolic diseases. In contrast, in
reverse genetics, or positional cloning [11, the aim is to isolate
a gene without reference to a specific protein or without any
functional assay useful in its detection. Through analysis of
restriction-fragment length polymorphisms (RFLP) and cytoge-
netic methods in affected families, morbid loci have been linked
to various DNA markers located on the human genome. In
some inherited diseases, mapping of the gene has been followed
by identification of the gene itself, of the mutation(s) responsi-
ble for the disorder, and finally of the gene product, thus
opening new avenues in the understanding of the disease
process. Duchenne muscular dystrophy, cystic fibrosis and
neurofibromatosis are recent examples where decisive progress
has been achieved through positional cloning.
Progress in molecular genetics has added new dimensions to
genetic heterogeneity. In addition to "classical" heterogeneity
(that is, a similar phenotype being related to different defective
genes, with similar or different modes of inheritance), molecular
heterogeneity has emerged: within the same gene, in various
kindreds different DNA lesions are detected, all responsible for
a similar or related phenotype. In very rare cases, exemplified
by sickle cell disease, a single mutation in one particular gene
causes the disorder. In contrast, in most inherited diseases
genetic molecular heterogeneity is the rule, such as in osteo-
genesis imperfecta where more than 70 DNA defects have been
demonstrated [21. In some diseases, a DNA defect predomi-
nates in some populations, such as the SF508 microdeletion in
cystic fibrosis. In other cases, no predominant DNA lesion is
found. Genetic molecular heterogeneity has been demonstrated
recently in Alport syndrome. Emphasis will be put in this
review on the methods used for detecting gene defects.
Finally, the molecular approach in inherited disorders not
only considerably extended our understanding, but also
changed our clinical attitudes. Inherited diseases have long
been considered a consequence of immutable fate and unre-
sponsive to therapy. The possibilities of presymptomatic test-
ing, prenatal diagnosis, prediction of some complications, and
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in some cases, specific therapy, have recently emerged. Further
progress can be expected in the coming decades. Consequently,
new boundaries of the diseases based not on phenotypes but on
genotypes will progressively be delineated, and new ethical
issues concerning early diagnosis have already been raised,
most particularly in late-onset inherited disorders such as
Hungtinton disease and autosomal-dominant polycystic kidney
disease.
Reverse versus classical genetics
Reverse genetics (or positional cloning)
Autosomal-dominant polycystic kidney disease (ADPKD)
was the first example of successful reverse genetics in the field
of nephrology. In 1985, Reeders et al found linkage between the
morbid locus (further denominated PKD1) and the a globlin
gene cluster and polymorphic markers located on the short arm
of chromosome 16 [3]. In the following years, an extensive and
detailed map of chromosome 16p has been developed. The map
of the 750 kb PKDI region of l6p. 13.3 has been established,
bracketed by two flanking markers, 26-6 proximally and GGG1
distally [4]. This region contains more than 20 genes. Most of
these are expressed in many tissues, including the kidney. One
of these genes has striking homology with a gene believed to
encode the 17 kD component of the vacuolar HATPase. No
disease-specific alleles of this gene have been identified [5]. The
main challenge is to identify the ADPKD gene, in the absence of
information on the gene function, requiring a gene-by-gene
search of the mutation(s). The methods available have been
reviewed by Collins [1].
The information on pathophysiology of cyst formation and
progression have been recently reviewed by Gabow [6]. Atten-
tion has been concentrated on two mechanisms: fluid accumu-
lation and cell proliferation of the cyst epithelium. Of interest,
the epidermal growth factor (EGF) receptor is mislocated to
apical cell surfaces (like Na, K-ATPase) in the cpk mouse with
congenital polycystic disease [7] and in ADPKD cysts [8],
contributing to epithelial hypersensitivity to EGF and possibly
mediating epithelial cell hyperplasia and/or transport abnormal-
ities.
Genetic heterogeneity has been documented in ADPKD.
Several groups have identified families in which the mutation
responsible for ADPKD is not linked to chromosome 16 mark-
ers [9]. The frequency of "unlinked" forms varies from one
series to another, ranging from 0% to 15% [10].
Reverse genetics can benefit from the data obtained in an animal
model of the human disease. The mouse cpk-cpk recessive poly-
cystic kidney disease shares some similarities with human auto-
somal recessive PKD. The cpk locus has been located on proximal
chromosome 12 [11]. However, it has been subsequently shown
that the gene responsible for ARPKD is not linked to markers on
chromosomes 2p23-2p25 or 7q22-q3 1, which are homologous to
proximal chromosome 12 in the cpk mouse [12, 13].
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Table I. Available data on gene location or function in the main inherited diseases with renal involvement
Mode of
Disease inheritance Symbol Assignment Cloned? Gene product
ADPKD AD PKDI 16pl3.3 -
AD PKD2 ? -
ARPKD AR ? -
Nephronophthisisa AR NPH 2p —
Alport syndrome XD ATS Xq22
Xq22
COL4A5
COL4A6?
a5(IV) collagen
a6(IV) collagen
AR 2q35-q36
2q35-q36
COL4A3
COL4A4?
a3(IV) collagen
a4(IV) collagen
Nail patella AD
Denys-Drash syndrom&'
NPS1
WTI
9q34
I lpl3
—
+ Zinc finger protein
Oculocerebrorenal XR OCRL Xq25-q26 + Inositol poly-
syndrome of Lowe phosphatase
Congenital nephrogenic XR DIR Xq27-q28 + Vasopressin
diabetes insipidus receptor V2
Osteopetrosis with renal XR CA2 8q22 + Carbonic
tubular acidosis anhydrase
Urolithiasis AR PHI + Alanine glyoxylate
Primary hyperoxaluria aminotransferase
2,8 dihydroxyadenine AR APRT 16q24 + APRT
X-linked [111] XR Xpll.22 —
Fabry disease XR GLA Xq2l .3-q22 + Galactosidase, a
LCAT deficiency AR LCAT 16q22. I + LCAT
Von Hippel Lindau AD VHL 3p25-p26 — Tumor suppressor
gene?
Tuberous sclerosis AD TSC1 9q34.l-34.2 —
AD TSC2 l6pl3L3 —
Genetic amyloidosis with prominent renal involvement:
FMF AR l6p —
FAPII AD TFR l8qll.2-ql2.l + Transthyretin
FAP Ill AD APOAL I 1q23-q24 + Apolipoprotein Al
Finnish type AD GSN 9q32-q34 + Gelsolin
Ostertag nephropathy AD APOAL 1 lq23-q24 + Apolipoprotein Al
AD 4q28 + a Fibrinogen [112]
AD 12 + Lysozyme [113]
Abbreviations are: ADPKD, autosomal-dominant polycystic kidney disease; ARPKD, autosomal-recessive polycystic kidney disease; AD,
autosomal dominant; AR, autosomal recessive; XR, X-linked, recessive; XD, X-linked, dominant; APRT, adenine-phospho-ribosyl-transferase,
LCAT, lecithin:cholesterol acyltransferase; FMF, familial Mediterranean fever; AA, amyloidosis; FAP, familial amyloid polyneuropathy.
a Recessive medullary cystic kidney disease; b with diffuse mesangial sclerosis, Wilms' tumor and male pseudohermaphroditism
Positional cloning has also been successfully used in other
inherited renal disorders, such as in Lowe oculocerebrorenal
syndrome (OCRL), an X-linked recessive disorder characterized
by congenital cataract, mental retardation and renal tubular dys-
function. Linkage analysis placed the OCRL locus in the Xq24-
q26 region. Subsequently, Reffly, Lewis and Nussbaum took
advantage of a de novo translocation t(X;3) (q25;q27) in a female
patient with OCRL to identify additional tightly linked flanking
markers [141. This observation, together with the balanced X;20
chromosomal translocation with the X chromosome breakpoint at
q26-1 in another girl with OCRL [15], is in agreement with the
statement that X-linked recessive disorders expressed in female
patients are often associated with X; autosomal translocation. It
has been suggested that preferential inactivation of the normal X
chromosome accounts for the full expression of the disease in
females. The translocation breakpoint can be used as a cytoge-
netic marker for the disease, based on the model that a gene for
OCRL is deleted or disrupted at the translocation breakpoint, This
approach led Attree et al [16] to isolate the OCRL gene, using
yeast artificial chromosomes (YACs) whose human inserts form a
contiguous region overlapping the breakpoint of the t(X;3) trans-
location. The transcript is absent in both female OCRL patients
with X; autosome translocation and it is absent or abnormally
sized in 9 of 13 unrelated male OCRL patients with no detectable
genomic rearrangement. This gene encodes a protein with high
homology to human inositol polyphosphate-5-phosphatase, sug-
gesting that OCRL may be an inborn error of inositol phosphate
metabolism.
The most recent success of positional mapping in renal diseases
has been achieved by Antignac et al who have studied 22 families
with juvenile nephronophthisis-medullary cystic disease complex
[which accounts for approximately 15% of the causes of end-stage
renal disease (ESRD) in children]. The gene responsible for purely
renal forms has been located to chromosome 2p. Furthermore,
linkage analysis suggests exclusion of Senior-Loken syndrome
(NPH associated with Leber amaurosis) from the same region
[17]. Information on location and function of the genes involved in
kidney diseases will be found in Table 1.
Classical genetics
Classical genetics has been successfully undertaken in some
inherited metabolic disorders with prominent kidney involve-
ment (Table 1),
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Fabty's disease. This is an X-linked recessive disorder re-
sulting from deficient activity of the lysosomal hydrolase,
a-galactosidase A. This defect leads to progressive accumula-
tion of neutral glycosphingolipids with terminal a-galactosyl
moieties, in various tissues including the kidneys, responsible
for end-stage renal disease in affected hemizygous males in the
fourth decade of life (18]. Human a-galactosidase has been
characterized and purified [refs. in 191. Subsequently, the
cDNA encoding this enzyme was isolated and the gene struc-
ture characterized. The genomic sequence is approximately 12
kb in length, contains seven exons, and has been mapped to the
region Xq21 .33- Xq22 by in situ hybridization. Using Southern
blot analysis, Bernstein et al [19] first identified the molecular
lesions in the a-galactosidase gene. In affected hemizygous
males from 130 unrelated families with Fabry's disease, they
found six gene rearrangements (4.6% of the families) and a point
mutation, mapped to exon 7.
Genetic heterogeneity (see below) may be expected in this
disease since: (1) atypical variants of the disorder are known,
including cases without angiokeratoma, the typical skin lesion
of Fabry's disease, and variants in which diseaese is limited to
the myocardium [20]; (2) classically affected hemizygotes with
no detectable enzymatic activity may have nonfunctional im-
munologically cross-reactive enzyme protein (CRM+) or no
detectable enzyme protein (CRM-); (3) a-galactosidase, like
other lysosomal enzymes, undergoes synthesis as a precursor
glycopeptide, cleavage of the signal peptide, and carbohydrate
modifications in the Golgi apparatus and lysosomes. Several
types of enzyme defects have been recognized, related to
abnormal synthesis, stability or processing of the enzyme
protein [21]. These findings suggest the occurrence of a variety
of mutations (see below).
Primary hyperoxaluria type I (PHI). PHI is a good example
of the recent molecular approach which has provided new
insight into the molecular mechanisms of the disorder, as well
as new approaches to therapy. PH! is a rare autosomal reces-
sive, inborn disorder of glyoxylate metabolism which is char-
acterized biochemically by increased synthesis and excretion of
oxalate and glycolate. Oxalate overload is responsible for the
clinical manifestations, that is, urolithiasis, nephrocalcinosis,
ESRD and systemic oxalosis, which develops mainly in dialysis
patients.
The first step, to identify the enzyme deficiency, was
achieved in 1986. The defect involves a liver-specific peroxiso-
mal enzyme, alanine glyoxylate aminotransferase 1 (AGT),
resulting in defective transamination of glyoxylate to glycine,
and in increased oxidation of glyoxylate to oxalate [refs. in 22].
Clinical heterogeneity is well documented in PH 1: ESRD
may be reached from early childhood to adulthood, over 50
years of age. As had been shown previously, some patients (4 of
59 AGT deficient patients in the series reported by Danpure
[22]) are responsive to pharmacological doses of pyridoxine
(pyridoxal phosphate is a cofactor for AGT). The biochemical
heterogeneity of PH 1 was subsequently demonstrated.
Approximately 50% of the patients studied by Danpure [22]
did not have hepatic AGT enzyme activity whereas the others
had residual enzyme activities. Unfortunately, the level of
residual AGT in the liver does not very closely parallel the
severity of the phenotype, and cannot therefore be used as a
good prognostic factor [22]. Subcellular distribution of liver
AGT is species specific. In the human (as in the rabbit, guinea
pig and macaque), AGT is confined to the peroxisome, whereas
in the cat and dog it is mitochondrial, and in the rat and mouse
it is located in both subcellular organelles. The localization of
AGT could be studied in liver specimens of PH1 patients since
in some of them, with or without residual enzyme activity,
immunoreactive AGT protein was detectable. All except one of
the six patients with AGT protein and no enzyme activity had a
normal peroxisomal subcellular distribution of AGT. In con-
trast, in all 14 patients with AGT protein and residual enzyme
activity, the majority of the hepatic AGT was mislocalized,
erroneously routed to mitochondrion instead of peroxisome
[23].
To explain the molecular basis of this rerouting phenomenon,
the nucleotide sequence of normal human peroxisomal AGT
cDNA and the cDNA of a PHI patient with mitochondrial AGT
were determined. Three point mutations were identified [24]. It
was subsequently shown by the same group [25] that one of the
substitutions, a proline-to-leucine at residue 11, is necessary
and sufficient for the generation of a mitochondrial targeting
sequence in the AGT protein. The N-terminal 19 amino acids of
AGT with this substitution are sufficient to target several
enzymes to mitochondria, as was demonstrated by in vitro
mutagenesis and in an in vitro mitochondrial import system.
As soon as the liver was recognized as the site of AGT
synthesis, combined liver and kidney transplantation or isolated
liver transplantion was performed in PHi patients. The indica-
tions for such treatment have been recently reviewed [26—28].
The diagnosis of PHi has also benefited from the biochemical
and molecular advances. The diagnosis of PH! is based on
increased urinary oxalate and glycolate excretion, but about
25% of the patients with AGT deficiency lack hyperglycolic
aciduria [26]. Determination of AGT activity on a liver biopsy
specimen is therefore mandatory when liver transplantation is
contemplated and biochemical diagnosis has not been clearly
established. Obviously, the need for preoperative liver biopsy
will be reduced in the near future when DNA analysis provides
diagnosis in families with identified molecular defects. Prenatal
exclusion of PHi has been performed by using fetal liver biopsy
and AGT assay [29]. Prenatal diagnosis will also be greatly
facilitated by DNA testing.
Candidate gene approach
A third type of approach which combines both classical and
reverse genetics has been used in molecular genetics, that is,
the candidate gene approach. It rests on the selection of
candidate gene(s) whose defect could be involved in the patho-
genesis of the disease. This hypothesis is subsequently tested
by linkage study. This approach has been used, for example, in
retinitis pigmentosa (rhodopsin gene), in familial hypertrophic
cardiomyopathy (cardiac f myosin heavy chain gene) and in
type 2 diabetes mellitus (glucokinase gene). Recently it has
been successful in hyperkalemic periodic paralysis (HYPP) (or
Garmstorp disease), a very rare disease which is of interest for
nephrologists. On the basis of electrophysiological studies,
Fontaine et al have hypothesized that this disease could be due
to a defect in the skeletal muscle cell sodium channel a-subunit
gene (SCN4A). Cosegregation of a given allele and the disease
was found in an affected kindred. A linkage between the Na
channel and HYPP was therefore established [30]. This was
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Fig. 1. Vasopressin V2 receptor mutations in
nephrogenic diabetes insipidus. The V2
receptor is a member of the 0-protein-coupled
receptor family possessing the characteristic
seven membrane-spanning regions. The
predicted extracellular domains are identified
as EL to Ely, and predicted cytoplasmic
domains are identified as CI to CIV, where
CIV is the carboxy-terminal sequence. Filled
circles denote substitutions; the nonsense
mutation is shown by a dotted circle; brackets
represent in-frame deletion. Frameshift
mutations are shown by a dash line; they
result in the incorporation of several amino
acids of non-receptor sequence before
reaching a stop codon (adapted from [40]).
confirmed by nucleotide sequencing of the a-subunit coding
region which demonstrated the point mutation involved [31]. Of
great interest is the subsequent identification of a temperature
sensitive mutation in the SCN4A gene responsible for a related
but distinct disorder, Paramyotonia Congenita (PC), thus estab-
lishing that HYPP and PC are allelic disorders [32].
A comparable approach, combining reverse genetics and the
candidate gene approach, has been successful in nephrogenic
diabetes insipidus (NDI), a rare X-linked recessive disorder
[33]. Linkage studies have assigned the NDI locus to the
subtelomeric region of the long arm of the X chromosome
(Xq28) [34]. ND! is characterized by resistance to the antidi-
uretic action of vasopressin, suggesting the renal cyclic-AMP
dependent vasopressin receptor (V2) gene as a candidate locus.
Recently, the V2 receptor gene was cloned by two different
laboratories [35, 36] and mapped to the long arm of the X
chromosome. Identification of several different molecular de-
fects in this gene in ND! patients (Fig. I) confirmed that the
ND! gene and the V2 receptor gene are identical [37—39].
The paradigm of Alport syndrome: Combined reverse and
classical genetics
Alport syndrome (AS), defined as progressive hereditary
nephritis with sensorineural hearing loss, is a heterogeneous
disease from the point of view of both the geneticist and the
nephrologist. Three modes of inheritance have been described.
In 80 to 85% of families, inheritance is compatible with X-linked
dominant transmission whereas in others autosomal dominant
transmission, characterized by father-to-son transmission, is
assumed. In a small percent of kindreds, autosomal recessive
transmission has been suggested, the disease being expressed in
the offspring of consanguineous parents [41, 421.
The correlation between patterns of inheritance and clinical
subtypes is not clearcut. The classification into six subtypes
proposed by Atkin, Gregory and Border [43], although cor-
rectly reflecting the two main rates of progression to ESRD
(juvenile type, type I! and adult type, type II!), suffers from the
lack of characterization of type I transmission (X-linked or
autosomal dominant). Interestingly, this classification raises the
possibility of AS without deafness (type IV), which has been
confirmed at the molecular level as discussed below. Both
reverse and classical genetics have been used to locate the
Alport gene and characterize the molecular defects in X-linked
AS.
Reverse genetics in AS. Genetic linkage studies in AS have
focused on families with the X-linked form. The first confirma-
tion of X-linkage by genetic marker analysis came from Men-
love et al in 1985 [44] who proved linkage to the DXS3 locus in
three kindreds in Utah. Subsequently, several other groups
[45—48] also suggested that the gene is localized in the middle of
the long arm of the X chromosome at Xq21-22. From these
studies the X-linked form of AS appears to be homogeneous, at
least in terms of its linkage pattern. Furthermore, data suggest-
ing that the linkage on the X chromosome is similar in heredi-
tary nephritis with or without deafness have been provided [47,
48]. However, for the past five years, this reverse genetics
approach has not allowed cloning of the AS gene.
Identification of the X-linked and autosomal AS genes
through classical genetics. Characteristic ultrastructural abnor-
malities seen in the GBM, such as splitting and thickening with
focal thinning of the lamina densa, led to the hypothesis of an
alteration in type IV collagen, the major GBM structural
component [reviewed in 49]. Subsequently, immunohistochem-
ical studies using antibodies directed against the non-collage-
nous domain (NC 1) of type IV collagen showed impaired GBM
reactivity in some AS kindreds [50—54]. Several different anti-
bodies were used, among them human anti-GBM sera, Good-
pasture (GP) renal eluates and monoclonal antibodies directed
against the OP antigen.
Type IV collagen is a heterotrimeric molecule composed of
three a chains, each containing a carboxy-terminal NC1 domain
and an amino-terminal collagenous domain characterized by a
frequently interrupted Gly-X-Y repeat sequence. The first two
identified chains, al(IV) and a2(IV), have been cloned and
mapped to the 13q terminus [55] (Fig. 2); thus they cannot be
involved in an X-linked disorder. Subsequently [56, 57], two
other chains, a3 and a4, were identified from collagenase
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Fig. 2. Schematic representation of the type
IV collagen genes. The genes encoding for
al(IV) and a2(IV) are located head to head on
chromosome 13q34. Similarly, the genes
encoding for a3(IV) and a4(IV) are on
chromosome 2q35-q37 and those encoding for
a5(IV) and a6(IV) are on chromosome Xq22.
Homology studies established that the type IV
collagens can be divided into two stuctural
famih . the aI(IV)-like family: al(IV),
a3(IV), a5(IV) and the a2(IV)-like family,
a2(IV), a4(IV), a6(LV).
digestion of both glomerular and lens basement membrane,
each yielding a 28 kd monomer in immunoblotting studies. They
were partially sequenced at the amino acid level, and very
recently cloned and mapped to chromosome 2 [58—60]. The
Goodpasture antigen has been shown to be located in the a3(IV)
NC1 domain [56, 61, 62].
The existence of a fifth a(IV) chain was first suggested by
Kashtan et a! [52], who characterized a human anti-GBM
antibody referred to as FNS 1, recognizing a collagen IV NC
domain 26 kd monomer, both in the GBM and in the epidermal
basement membrane. This was confirmed by Tryggvason et a!
[63], who cloned a novel type IV collagen gene (COL4A5)
coding for the a5(IV) chain. Subsequent characterization
showed a 6.6 kb mRNA coding for 1685 amino acids, including
a putative 26 residue signal peptide, a 1430 residue collagenous
domain and a 229 residue carboxyterminal NC domain, closely
related to al(IV) [64]. This a5(IV) chain was shown to be
expressed in the lung and kidney as a minor component
compared to al(IV) and a2(IV) at the mRNA level. Its renal
distribution determined by immunostaining seems to be re-
stricted to the GBM, while the epidermal basement membrane
is negative [65]. Most importantly, in situ hybridization allowed
mapping of this COL4AS gene to chromosome X at band q22,
like AS. Therefore it became a very good candidate gene for
AS. Indeed, Barker et al [66] described three different muta-
tions in three families with AS among 18 studied in Utah. Very
recently, a sixth gene, COL4A6, encoding a new type IV
collagen chain, a6(IV), was cloned by two different laborato-
ries. Furthermore, it was shown to be located head to head with
a5(IV) on Xq22 and to be homologous to a2(IV) [67, 68].
Whether mutations in COL4A6 account for some cases of
X-linked AS remains to be established. Thus, type IV collagens
could be divided into two structural families [67]: the al(IV)-
like family, al(IV), a3(IV), a5(IV); and the a2(IV)-like family,
cr2(IV), a4(IV), and a6(IV) (Fig. 2).
The existence of autosomal recessive forms has been con-
firmed by molecular studies. In three consanguineous families a
linkage was found with the gene encoding the a3 (IV) chain [69],
and subsequently two different mutations in this COL4A3 gene
were identified in two other consanguineous families [70, 71].
Genetic molecular heterogeneity
Genetic molecular (or allelic) heterogeneity in X-linked Alport
syndrome
How can mutations be detected inside a cloned gene? The
first step usually consists in looking for gross alterations of the
gene (those involving more than 100-200 base-pairs) which are
easier to detect by molecular diagnostic methods. The basic
method is Southern blotting, in which gross alterations of the
gene such as deletions, insertions or rearrangements within the
gene will modify the size of the restriction fragments seen on
Southern blots.
This technique was used to detect the first mutations in AS.
Several major COL4AS gene rearrangements have now been
described, primarily deletions (see ref. in [64]). All of them
appear to be responsible for severe juvenile type AS. Three
complete COL4A5 deletions were found associated with post-
transplant anti-GBM nephritis (see below). Deletions involving
the 5' part of the gene, intragenic deletions and deletions not
limited at the 3' part of the gene have been identified. No
deletion "hot spot" was identified, as has been described in the
dystrophin gene for example. The severity of the aS chain
alteration is related to the preservation ("in frame deletions")
or not ("frameshift deletions") of the reading frame at the
mRNA level, and could eventually influence the severity of the
phenotype. We [72] were able to identify 12 deletions among 77
families studied, giving a deletion ratio of 16% for this gene.
This seems to exceed the usual 1 to 5% proportion of gross
lesions of many genes. For example,fewer than 5% of the
identified lesions in the factor VIII gene responsible for hemo-
philia A represent major rearrangements such as deletions.[73}.
On the other hand, the huge dystrophin gene (about 2106 kb) is
deleted in 50 to 60% of patients with Duchenne muscular
dystrophy (DMD) [74]. Deletions also occur with relative
frequency in tandemly duplicated genes such as the a-globin
locus, which can be altered by unequal cross-over during
meiosis.
Complete deletion of an X-localized gene, easily detectable in
hemizygous males by the absence of restriction fragments, may
be difficult to identify in heterozygous females because the wild
a2(IV)
5, 3,
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type allele will give the normal restriction pattern, albeit 50%
weaker in intensity than normal. Only gene dosage, using a
control probe as a housekeeping gene which is normally ex-
pressed in both patients and controls, will allow detection of a
50% reduction in the signal intensity ratio and therefore detec-
tion of heterozygous female carriers. On the contrary, diagnosis
of the heterozygous state may be easy if the DNA probe used
for Southern analysis hybridizes with junction fragments of
abnormal size from one allele, together with the normal size
fragments from the other allele.
More recently, polymerase chain reaction (PCR) amplifica-
tion has been applied to the detection of deletions, thus avoid-
ing the use of time-consuming Southern blotting. Either
genomic or complementary DNA can be studied. In the first
case, several exons of a gene can be amplified with several pairs
of oligonucleotide primers in a single reaction called multiplex
PCR and visualized on an appropriate gel. The lack of amplifi-
cation of one exon indicates its deletion. This method was first
applied to the dystrophin gene [74]. When the studied gene is
large, such as the COL4A5 gene which contains 51 small exons
spread over 150 kb of genomic DNA, it can be easier and
time-saving to directly study the compacted coding sequence in
the cDNA. Even if the gene is expressed in a tissue specific
way, as COL4A5 most probably is, one can take advantage of
the illegitimate transcription of any gene in any cell type [75] to
study easily accessible cells such as lymphocytes. This has
been proven feasible by using PCR amplification of lymphocyte
mRNA to characterize truncated transcripts of the dystrophin
gene [761, as well to identify a point mutation in an AS family
[77]. However, as discussed above, gross alterations of DNA
usually account for only a minority of disease causing muta-
tions. How does one search for mutations involving a single or
a few nucleotides?
When dealing with a polyallelic disease as AS certainly is,
mutations can probably occur anywhere inside the gene, which
therefore must be completely screened. The first step can be
performed together with the screening for gross rearrangements
by Southern blotting. In fact, point mutations may alter restric-
tion recognition sites and then change the size of the DNA
fragments generated by restriction endonuclease digestion of
the gene studied. However, only about 5 to 10% of mutations
can be detected in this way [73].
This approach allowed the first point mutations in COL4A5 to
be identified [64]. Detection of a point mutation is easy when
the disease is monoallelic, such as sickle cell disease, where the
same A to T transversion in the sixth codon, converting a
glutarnine residue to valine, is responsible for the inherited
defect in all patients. Unfortunately, this is a rare condition
since most inherited disorders are heterogeneous at the molec-
ular level. However, once a precise mutation has been identi-
fied inside a family or the population of a limited region, it can
be sought relatively easily. If the mutation abolishes a restric-
tion enzyme recognition site, lack of digestion of the PCR
amplified DNA with the appropriate endonuclease will allow its
detection. If not, hybridization of the amplified DNA with
allele-speqfic oligonucleotide probes, homologous to either the
normal or the mutant sequence, will determine whether the
mutant allele is present and if this is the case, whether the
studied individual is heterozygous or homozygous for this
mutation.
Several methods have recently been described to detect
unknown mutations [reviewed in 78]. All of them rely on PCR
amplification of DNA followed by chemical or enzymatic
analysis. The main methods used are denaturing gradient gel
electrophoresis (DGGE) of an amplified fragment, chemical
cleavage of mismatched base method (also called HOT after
the chemicals used), ribonuclease A digestion which can cleave
a labeled RNA probe if a mismatch has occurred between the
wild type probe and the mutant DNA, and single strand
conformation polymorphism (SSCP) [79]. The ultimate com-
plete characterization of the mutation relies on sequencing of
the PCR product. Whenever a point mutation is identified in a
gene, it is necessary to consider whether the point mutation-
induced changes in the protein are actually responsible for the
disease. This can be assumed if the single base substitution is
not a (neutral) polymorphism found in some unaffected individ-
uals, if the mutation segregates with the disease inside the
family and, whenever possible, if the substituted amino acid is
known to play an important role in the protein structure. The
final proof could come from transgenic animals (essentially
mice) expressing the mutated COL4A5 gene. Reproduction of
the same disease phenotype as humans definitely proves the
pathogenic role of the mutation.
More than 30 microdeletions and point mutations have been
identified in COL4AS [reviewed in 64]. They seem to happen all
over the gene, without a recurrent mutation being responsible
for AS in a subgroup of patients. Some of them involve the
collagenous domain of the aS chain. They all are responsible for
glycine substitutions in the Gly-X-Y repeat sequence character-
istic of the collagenous chains, as it is found in the COL1A1 and
COLIA2 genes in association with osteogenesis imperfecta [21.
The suppression of a conserved glycine in the Gly-X-Y repeat
sequence characteristic of the collagenous domain is supposed
to impair the zipper-like folding of the triple helix. These
glycine substitutions are associated with different phenotypes,
both juvenile and adult type AS, with or without hearing loss,
which cannot be predicted from the location of the mutation. Of
interest, similar molecular heterogeneity has been documented
in other inherited diseases involving fibrillar collagen. In osteo-
genesis imperfecta, over 70 different mutations have been
identified in the type I procollagen genes. They generate a large
variety of phenotypes, the severity of which cannot often be
predicted from the genotypic lesions [2]. Other mutations
involve the non-collagenous domain of the aS chain. They can
create a stop codon leading to a truncated chain or involve very
conserved amino acids known to play a role in the structural
conformation of the NC1 domain, as the cysteine residues [64].
The interactions between the different a(IV) chains in normal
and Alport GBM remain to be clarified. Previous studies have
demonstrated the absence of the GP antigen in the GBM of
most male patients affected with AS. This was confirmed using
mono- or polyclonal antibodies against the NC 1 domain of the
a3 chain, which contains the GP antigen. The absence of the a4
(IV) chain NCI domain has been documented in some cases
[80]. The reason why mutations in the COL4AS gene found in
AS kindreds are sometimes associated with abnormal distribu-
tion of the a3 and a4 chains remains unclear. It can be assumed
that the COL4A3 and COL4A4 genes, mapped to chromosome
2, are not directly involved in X-linked AS due to mutations in
the COL4A5 gene. It has been hypothesized by Kashtan et al
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[81, 82] that the abnormal conformation of the a5(IV) chain
secondary to a mutated COL4AS gene affects the integration of
the a3 and a4 chains within the type IV collagen molecule. Data
on the structural conformation and interactions of the heterot-
rimers inside the GBM are still lacking. We have reported [80]
two male patients with intragenic deletion in the COL4A5 gene
whose GBM lacks expression of the a3 and a4 chains. This
finding favors the hypothesis of deletion-induced conforma-
tional changes in aS directly responsible for the lack of a3 and
a4 integration in the collagen IV heterotrimer. Of interest, lack
of antigenic expression of the a3 chain is restricted to juvenile,
severe type X-linked AS [80]. In situ hybridization will tell us
whether the COL4A3 mRNA is normally expressed in kidneys
of these patients. Eventually, these findings could suggest that
the a3 and a4 chains are present in heterotrimers only in
association with the aS (IV) chain in the GBM.
Genetic molecular heterogeneity in inherited metabolic
diseases with kidney involvement
In Fabry's disease, molecular heterogeneity was demon-
strated in the first studies performed by Bernstein et al [19]:
among the six gene rearrangements, five partial deletions and
one partial duplication were recognized. In addition to the point
mutation reported by Bernstein et al [19], other single-base
substitutions have been identified. In two Japanese families
with classic Fabry phenotype and no detectable a-galactosidase
A activity, a 0-to-A transition in exon I (codon 44) substituted
a termination codon (TAG) for a tryptophan codon (TGG) in
one family [83]. A missense mutation involving a C-to-T tran-
sition at nucleotide 118 resulted in an amino acid substitution of
Pro-40 by Ser in the other one [84]. In another Japanese family
an intronic mutation at a consensus splice site of intron 6 has
been documented, and resulted in the deletion of the entire
exon 6 sequence [83]. In addition, in patients with late-onset
cardiac involvement and significant residual a-galactosidase
activity, two different point mutations in exon 6 have been
found [20, 83]. Enzymatic detection of heterozygotes may be
difficult in families since the levels of a-galactosidase activity
may range from zero to normal, owing to random inactivation of
the X chromosome. In older heterozygotes, the levels of
a-galactosidase activity may increase with age, due to demeth-
ylation and subsequent reactivation of X-chromosomal genes
[19]. Direct detection of the DNA molecular defects circum-
vents these drawbacks.
Genetic heterogeneity is not limited to lysosomal metabolic
diseases. In other metabolic diseases with kidney involvement,
similar observations are being made and will be progressively
extended in the future. Familial deficiency of lecithin:choles-
terol acyltransferase (LCAT) is an autosomal recessive disease
characterized by an inability to esterify plasma cholesterol and
by abnormal deposition of unesterified cholesterol in tissues,
including the kidneys. The clinical manifestations comprise
corneal opacities, hemolytic anemia, premature atherosclero-
sis, and renal involvement leading to ESRD. Cloning of cDNA
and genomic DNA for human LCAT revealed that the gene
consists of six exons [86] and is localized on chromosome 16.
Sixteen different point mutations have been described in vari-
ous populations [reviewed in 87, 88]. It is clear that distinct
mutations can cause differences in plasma LCAT activity and
mass, leading to differential phenotypic expression of the dis-
ease. For example, two separate missense mutations were
identified in exon 6 in two different patients, with one having no
renal complications and a partially defective enzyme, and the
other massive proteinuria and completely abolished enzyme
activity [87]. Of interest, a molecular defect in the LCAT gene
was also identified in another disease, the fish eye disease,
which is characterized by massive bilateral corneal opacities
and by a specific inability to esterify cholesterol in HDL,
whereas the ability to esterify cholesterol in plasma is preserved
[89].
Clinical implications of DNA testing
DNA testing is valuable for classifying atypical findings, for
predicting rare complications and for performing presymptom-
atic diagnosis in inherited diseases. This will be illustrated by
some examples taken in ADPKD and in Alport syndrome.
Methods available for DNA testing in patients and families
The development of new DNA-based diagnostic tests for
genetic disorders has created many opportunities to benefit
patients and families. However, criteria need to be established
in order to determine when a new diagnostic test has reached a
level of development where it can move from the domain of
research to that of clinical care. One must differentiate between
testing based on linkage analysis which obviously has different
inherent limitations than does the direct identification of known
mutations. For unknown disease loci tested by linked polymor-
phisms, a clinical DNA test should provide an answer with a
confidence interval of at least 95% [90]. DNA polymorphisms
flanking or within the gene of interest can be used as markers
for the mutant allele. In addition to the traditional DNA
polymorphisms identified by RFLPs, many genes have more
informative polymorphisms which consist of variable number of
tandem repeats of cytosine and adenosine [91]. These are
detected more easily by PCR amplification (Fig. 3). This ap-
proach has been recently successfully applied to ADPKD
genetic analysis [92]. Even for disease genes that are cloned,
molecular heterogeneity prevents rapid identification of the
precise molecular defect in a given family. If this molecular
defect has already been determined, presymptomatic testing
will be easy within the family. In contrast, the use of linkage
analysis still remains useful in the absence of knowledge of the
specific DNA defect in a given family.
Clinical consequences in ADPKD
Autosomal dominant PKD may be responsible for clinical
manifestations in early childhood, including ESRD. Gal et al
[931 have found that the gene locus in these families is linked to
the markers on the short arm of chromosome 16. However, the
occurrence of such rapid progression in some siblings in a given
family suggests that additional unknown genetic or environmen-
tal factors are involved. In contrast, there is no linkage with
these markers in families with autosomal recessive PKD. Au-
tosomal recessive and dominant forms of PKD are not allelic
[94]. Congenital hepatic fibrosis is characterized by periportal
fibrosis and intrahepatic bile duct proliferation, and often ac-
companied by portal hypertension. It is generally associated
with autosomal recessive PKD. However, there are several
reports of families in which congenital hepatic fibrosis and
ADPKD were associated. Cobben et al [95] have found in three
of such families close linkage between the mutation causing
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specific therapy could be indicated on knowledge of diagnosis,
such as in young subjects from ADPKD families with clustering
of intracranial aneurysms complicated by early rupture. We
share the view expressed by Watson, MacNicol and Wright that
only in very rare instances need the diagnosis of ADPKD be
established by DNA testing in subjects aged under 18 [96].The
positive consequences and the eventual negative impact of
presymptomatic diagnosis in asymptomatic individuals will not
be discussed in the present review, and the precautions re-
quired have been detailed elsewhere [96—98].
Prenatal diagnosis with gene linkage study on chorionic
villous sample has been performed at approximately the ninth
week of pregnancy in a limited number of cases when parents
had elected to have the pregnancy terminated [991. Although
many patients are keen to know whether their fetus is affected,
recent studies in Western countries indicate that few affected
subjects (4%) would consider termination of pregnancy for
ADPKD [100]. Attitudes of affected individuals may vary from
one country to another, according to differences in cultural
background, and possibly from one study to another according
to the proportion of dialysis patients tested [101]. Currently the
demand for prenatal diagnosis is low in most Western countries.
The Special Report of the National Kidney Foundation 1989
states that affected parents should be informed about the
availability of prenatal diagnosis (on the basis of linkage study
in the family) but should also be advised that the method so far
used does not predict the natural history of the disease [97].
Substantial numbers of ADPKD patients do not progress to
ESRD during their life span [reviewed in 981. This information
should be clearly given in genetic counseling interviews. Atti-
tudes toward presymptomatic testing may change in the light of
progress achieved in molecular genetics.
Fig. 3. Linkage analysis in two Alport syndrome families using micro-
satellite polymorphisms (CA repeats) located inside and close to the
COL4A5 gene at Xq22. A. Family history compatible with X-linked
inheritance. Alleles are numbered from 1 to 3. The genotypes are
indicated on the pedigree. The affected son (black square) inherited the
allele 3 from his heterozygous mother (1/3). The unaffected son (blank
square) inherited the allele 1. Three asymptomatic daughters were
identified as heterozygous for the mutated gene (genotype 2/3), while
the fourth daughter is not a carrier (1/2). B. Family history compatible
with X-linked inheritance. Two different microsatellites were studied
(top and bottom). The genotypes are indicated on the pedigree. All the
sons, the two affected and the three unaffected, inherited the same allele
from their mother (allele I with the first microsatellite, top, and allele 3
with the second microsatellite, bottom). This result excludes a COL4A5
mutation in this family. Since intermittent microscopic hematuria and
potential consanguinity has been documented for the parents, and
autosomal recessive mode of inheritance is very likely.
kidney disease and DNA markers on chromosome 16. This
observation clearly demonstrates that congenital hepatic fibro-
sis can be encountered in ADPKD patients (although the
genetic basis of congenital hepatic fibrosis is unknown since it is
not dominantly transmitted in the affected kindreds).
Presymptomatic diagnosis may be performed by DNA testing
by genetic linkage analysis in families. In ADPKD, DNA testing
may be valuable only in cases where ultrasonography is incon-
clusive, that is, in very young subjects. It may be useful in
potential living related kidney donors or in subjects in whom
Clinical implications in Alport syndrome
In Alport syndrome, DNA testing may have clinical applica-
tions. Variants of Alport syndrome can be correctly classified
on the basis of the molecular COL4A5 defects. In at least two
families with hereditary nephritis without hearing loss, two
different point mutations affecting the COL4A5 gene have been
identified [102, 103]. This suggests that at least some cases of
this entity belong to the spectrum of Alport syndrome. DNA
analysis has confirmed that the syndrome characterized by
diffuse leiomyomatosis, nerve deafness, cataract and progres-
sive nephritis also belongs to the Alport spectrum. Indeed, in
three families with leiomyomatosis, deletions in the 5' region of
the COL4A5 gene were found. This syndrome might be due to
the deletion of another gene located upstream from COL4A5
[104].
The results of kidney transplantation in Alport patients are
similar to those observed in non-Alport patients [105]. How-
ever, 1 to 5% of these patients develop circulating anti-GBM
antibodies after transplantation, leading to crescentic glomeru-
lonephntis in most of them [106]. Kashtan et al have speculated
that certain mutations at the Alport gene, such as large intra-
genic deletions or frame-shift mutation, may predispose to such
a complication by preventing development of immune tolerance
to the lacking protein product of the Alport gene [107]. How-
ever, it has been shown that post-transplant alloantibodies from
various AS patients bind to the a3(IV) NC domain of type IV
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collagen [108] while others do not [54]. No definitive informa-
tion is available with regard to binding of these alloantibodies to
aS(IV). Thus the tentative present hypothesis could be that an
alteration in the a5(IV) chain leads to a failure in incorporation
of the a3(IV) chain in type IV collagen heterotrimers inside the
GBM, thus preventing development of immune tolerance to the
lacking a3(IV) chain. We have collected information on 30
Alport patients who underwent kidney transplantation. Three
of them developed anti-GBM nephritis; two of these had a large
deletion of COL4A5 whereas the third one had no detectable
defect by Southern analysis. Of the 27 patients who did not
develop anti-GBM nephritis, two had large deletions in the
COL4A5 gene, strongly suggesting that the gene product was
unstable or absent (Antignac et al, manuscript in preparation).
Other cases with large deletions and post-transplant anti-GBM
nephritis have been reported [102, 109]. In addition to large
deletions, other DNA defects may severely alter gene products,
such as microdeletions which may cause a shift in the reading
frame, leading to a nonsense protein, point mutations which
may generate stop codons and lead to a truncated protein or
mutations affecting consensus splice sites [110]. More extensive
studies are required to test whether patients with some specific
DNA defects (such as preventing expression of the NC 1 do-
main) are at higher risk to develop such a complication than
others. In the family described by Kashtan et al [1071, two
cousins developed this complication but, surprisingly, two
other related males had successful kidney transplantation.
Other factors such as the antigen introduced with the graft and
the HLA class II molecules which present the antigen to the
immune system may play a role in the development of post-
transplant anti-GBM disease.
DNA testing may allow correct detection of asymptomatic
female carriers (Fig. 3). Indeed, female carriers may have
slight, intermittent or no urinary abnormalities. The clinical
diagnosis may therefore be hazardous. This may lead to erro-
neous determination of the mode of inheritance. In one large
Alport family, previously reported as having autosomal domi-
nant inheritance, careful clinical investigation and then DNA
testing indicated X-linked dominant transmission of a point
mutation in the COL4A5 gene [77]. Detection of asymptomatic
female carriers is crucial in view of kidney donation and for
genetic counseling. Genetic counseling rests first on correct
identification of the mode of inheritance since autosomal (re-
cessive and dominant) and X-linked dominant forms have been
described [38] (Fig. 3). The means of prenatal diagnosis, by
linkage study or by direct COL4A5 (and now COL4A3) study,
are available only in some families (see above). The desires of
the families need to be better investigated. In X-linked families,
they may differ according to the rate of progression to ESRD in
males from a given family.
BERTRAND KNEBELMANN, CORINNE ANTIGNAC,
MARIE-CLAIRE GUBLER and JEAN-PIERRE GRONFELD
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